中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
5期
856-857
,共2页
胰腺癌%甘露聚糖肽%介入化疗
胰腺癌%甘露聚糖肽%介入化療
이선암%감로취당태%개입화료
Pancreatic Cancer%Mannatide%Interventional Chemotherapy
目的：：探讨甘露聚糖肽联合介入化疗治疗晚期胰腺癌的临床效果。方法：选用2008年05月~2012年03月我院介入科和放疗科共收治晚期胰腺癌患者74例,随机分为观察组和对照组,各37例,均采用改良Seldinger法行股动脉穿刺,通过动脉置管,血管造影,确定靶血管,行动脉灌注化疗。同时观察组加用甘露聚糖肽注射液,静脉点滴,10mg/天。治疗周期为4周。结果：观察组患者治疗后疼痛缓解总有效率为83.78%,与对照组的62.15%比较具有统计学差异(P=0.036)。观察组治疗后生活质量(KPS评分)改善率为91.89%,与对照组的72.97%比较具有统计学差异(P=0.033)。观察组1年生存率、2年生存率均显著高于对照组(P值分别为0.038,0.036)。结论：应用甘露聚糖肽联合动脉灌注化疗治疗胰腺癌,能有效提高化疗的临床疗效,改善患者生活质量,延长生存时间。
目的：：探討甘露聚糖肽聯閤介入化療治療晚期胰腺癌的臨床效果。方法：選用2008年05月~2012年03月我院介入科和放療科共收治晚期胰腺癌患者74例,隨機分為觀察組和對照組,各37例,均採用改良Seldinger法行股動脈穿刺,通過動脈置管,血管造影,確定靶血管,行動脈灌註化療。同時觀察組加用甘露聚糖肽註射液,靜脈點滴,10mg/天。治療週期為4週。結果：觀察組患者治療後疼痛緩解總有效率為83.78%,與對照組的62.15%比較具有統計學差異(P=0.036)。觀察組治療後生活質量(KPS評分)改善率為91.89%,與對照組的72.97%比較具有統計學差異(P=0.033)。觀察組1年生存率、2年生存率均顯著高于對照組(P值分彆為0.038,0.036)。結論：應用甘露聚糖肽聯閤動脈灌註化療治療胰腺癌,能有效提高化療的臨床療效,改善患者生活質量,延長生存時間。
목적：：탐토감로취당태연합개입화료치료만기이선암적림상효과。방법：선용2008년05월~2012년03월아원개입과화방료과공수치만기이선암환자74례,수궤분위관찰조화대조조,각37례,균채용개량Seldinger법행고동맥천자,통과동맥치관,혈관조영,학정파혈관,행동맥관주화료。동시관찰조가용감로취당태주사액,정맥점적,10mg/천。치료주기위4주。결과：관찰조환자치료후동통완해총유효솔위83.78%,여대조조적62.15%비교구유통계학차이(P=0.036)。관찰조치료후생활질량(KPS평분)개선솔위91.89%,여대조조적72.97%비교구유통계학차이(P=0.033)。관찰조1년생존솔、2년생존솔균현저고우대조조(P치분별위0.038,0.036)。결론：응용감로취당태연합동맥관주화료치료이선암,능유효제고화료적림상료효,개선환자생활질량,연장생존시간。
Objective:To observe the clinical efficacy of mannatide combined with interventional therapy in the treatment of patients with advanced pancreatic cancer.Methods:74 patients with advanced pancreatic cancer admitted to interventional radiology and radiotherapy department in our hospital from May 2008 to March 2012 were randomly divided into treatment group and control group. Both groups were given modified Seldinger method for femoral artery puncture. By artery catheterization, angiography, the target vessels were determined and arterial infusion chemotherapy were given. The treatment group were given additional mannatide injection by intravenous, 10mg/day for 4 weeks.Results:The total effective rate of pain relief in the treatment group after treatment was 83.78%, with statistically difference from 62.15%in the control group (P=0.036). The improvement rate of quality of life (KPS score) in the observation group was 91.89% after treatment, with statistically difference from 72.97% in the control group (P=0.033).The 1-year and 2-year survival rates of the treatment group were significantly higher than that of the control group (P=0.038,0.036).Conclusion:The application of Mannatide combined with arterial infusion chemotherapy for pancreatic cancer can improve the clinical efficacy of chemotherapy effectively, improve quality of life and prolong survival time.
